Vimarsana
Biggest News Aggregation in the World

Page 5 - Thyroid Disorders News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thyroid Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thyroid Disorders Today - Breaking & Trending Today

Nearly 1 In 10 Indian Women Develop A Thyroid Disorder Before The Age Of 60 - Vimarsana News

Nearly 1 In 10 Indian Women Develop A Thyroid Disorder Before The Age Of 60

The most common thyroid disorder seen among adults in India is hypothyroidism. Read on to know the causes, symptoms and treatment of thyroid disorders. TheHealthSite.com

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial - Vimarsana News

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer - Vimarsana News

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

Results from Phase 3 KEYNOTE-966 to be presented at AACR 2023 Annual Meeting during Clinical Trials Plenary Session, included in official meeting press program and published simultaneously in The... | April 16, 2023

Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coform - Vimarsana News

Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coform

Blinded arms of the study will continue to further evaluate MK-7684A with docetaxel versus docetaxel aloneRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe...

Thyroid Disorders Are Prevalent Among School-Age Children: What Parents Should Know - Vimarsana News

Thyroid Disorders Are Prevalent Among School-Age Children: What Parents Should Know

Nearly 37 children per 1,000 are believed to have thyroid illness. Here are some signs and symptoms of hypothyroidism parents should look out for in kids. TheHealthSite.com